Evidence map›Paper›PMID 37237893›Full record

ReviewAntioxidants (Basel, Switzerland)2023

Apolipoprotein D in Oxidative Stress and Inflammation.

Guillaume Fyfe-Desmarais, Fréderik Desmarais, Éric Rassart, Catherine Mounier

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07673913 (Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression), which is not on this map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07673913 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Relationship Between Response to Transcranial Magnetic Stimulation and Peripheral Inflammatory and Neuroprotective Biomarkers in Patients With Treatment-Resistant Depression

TypeinterventionalSponsorGulhane Training and Research HospitalRan2026 to 2027Enrolled100ConditionsTreatment-resistant Depression (TRD), Major DepressionArmsIntermittent Theta Burst Stimulation (iTBS)
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 53 citations in OpenAlex.

  1. Persistent ZnAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Guillaume Fyfe-DesmaraisLaboratory of Metabolism of Lipids, Centre d'Excellence en Recherche sur les Maladies Orphelines-Fondation Courtois (CERMO-FC), Department of Biological Sciences, University of Quebec in Montreal (UQAM), 141 Av. du Président-Kennedy, Montreal, QC H2X 1Y4, Canada.
Fréderik DesmaraisDepartment of Medecine, Faculty of Medecine, Institut Universitaire de Cardiologie et de Pneumologie de Québec, 1050 Av. de la Médecine, Québec City, QC G1V 0A6, Canada.
Éric RassartLaboratory of Metabolism of Lipids, Centre d'Excellence en Recherche sur les Maladies Orphelines-Fondation Courtois (CERMO-FC), Department of Biological Sciences, University of Quebec in Montreal (UQAM), 141 Av. du Président-Kennedy, Montreal, QC H2X 1Y4, Canada.
Catherine MounierLaboratory of Metabolism of Lipids, Centre d'Excellence en Recherche sur les Maladies Orphelines-Fondation Courtois (CERMO-FC), Department of Biological Sciences, University of Quebec in Montreal (UQAM), 141 Av. du Président-Kennedy, Montreal, QC H2X 1Y4, Canada.
Université du Québec à Montréal · CAInstitut universitaire de cardiologie et de pneumologie de Québec · CA

Funding

Natural Sciences and Engineering Research Council RGPIN-2019-06738
6 · The paper itself

Abstract

Apolipoprotein D (ApoD) is lipocalin able to bind hydrophobic ligands. The APOD gene is upregulated in a number of pathologies, including Alzheimer's disease, Parkinson's disease, cancer, and hypothyroidism. Upregulation of ApoD is linked to decreased oxidative stress and inflammation in several models, including humans, mice, Drosophila melanogaster and plants. Studies suggest that the mechanism through which ApoD modulates oxidative stress and regulate inflammation is via its capacity to bind arachidonic acid (ARA). This polyunsaturated omega-6 fatty acid can be metabolised to generate large variety of pro-inflammatory mediators. ApoD serves as a sequester, blocking and/or altering arachidonic metabolism. In recent studies of diet-induced obesity, ApoD has been shown to modulate lipid mediators derived from ARA, but also from eicosapentaenoic acid and docosahexaenoic acid in an anti-inflammatory way. High levels of ApoD have also been linked to better metabolic health and inflammatory state in the round ligament of morbidly obese women. Since ApoD expression is upregulated in numerous diseases, it might serve as a therapeutic agent against pathologies aggravated by OS and inflammation such as many obesity comorbidities. This review will present the most recent findings underlying the central role of ApoD in the modulation of both OS and inflammation.

Indexed as

4-hydroxynonenalalzheimerarachidonic acidhigh density lipoproteinlipid peroxidationmalondialdehydemetabolismobesitypolyunsaturated fatty acidprostaglandins

Identifiers

PMID37237893
PMCPMC10215970
OpenAlexW4367596513

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.